Critical Care Management of the Patient With Anaphylaxis: A Concise Definitive Review.

Crit Care Med

Divisions of Infectious Disease, Pulmonary, Allergy and Immunology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC.

Published: May 2021

Objectives: Anaphylaxis is a rapidly progressive life-threatening syndrome manifesting as pruritus, urticaria, angioedema, bronchospasm and shock. The goal of this synthetic review is to provide a practical, updated approach to the evaluation and management of this disorder and associated complications.

Data Sources: A MEDLINE search was conducted with the MeSH of anaphylaxis, anaphylactic reaction, anaphylactic shock, refractory anaphylaxis and subheadings of diagnosis, classification, epidemiology, complications and pharmacology. The level of evidence supporting an intervention was evaluated based on the availability of randomized studies, expert opinion, case studies, reviews, practice parameters and other databases (including Cochrane).

Study Selection: Selected publications describing anaphylaxis, clinical trials, diagnosis, mechanisms, risk factors and management were retrieved (reviews, guidelines, clinical trials, case series) and their bibliographies were also reviewed to identify relevant publications.

Data Extraction: Data from the relevant publications were reviewed, summarized and the information synthesized.

Data Synthesis: This is a synthetic review and the data obtained from a literature review was utilized to describe current trends in the diagnosis and management of the patient with anaphylaxis with a special emphasis on newer evolving concepts of anaphylaxis endotypes and phenotypes, management of refractory anaphylaxis in the ICU setting and review of therapeutic options for the elderly patient, or the complicated patient with severe cardiorespiratory complications. Most of the recommendations come from practice parameters, case studies or expert opinions, with a dearth of randomized trials to support specific interventions.

Conclusion: Anaphylaxis is a rapidly progressive life-threatening disorder. The critical care physician needs to be familiar with the diagnosis, differential diagnosis, evaluation, and management of anaphylaxis. Skilled intervention in ICUs may be required for the patient with complicated, severe, or refractory anaphylaxis.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCM.0000000000004893DOI Listing

Publication Analysis

Top Keywords

refractory anaphylaxis
12
anaphylaxis
11
critical care
8
management patient
8
patient anaphylaxis
8
anaphylaxis rapidly
8
rapidly progressive
8
progressive life-threatening
8
synthetic review
8
evaluation management
8

Similar Publications

Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome.

Allergy Asthma Proc

January 2025

From the Section of Allergy, Asthma and Immunology, Medicine and Pediatrics, Pennsylvania State University School of Medicine, Hershey, Pennsylvania and.

Patients with mast cell activation syndrome (MCAS) can be refractory to standard antimediator therapy. Alternative treatment options to reduce disease burden and improve quality of life are needed. To compile the evidence that supports the use of omalizumab for patients with refractory MCAS.

View Article and Find Full Text PDF

Do no harm: An ethical approach to refractory anaphylaxis to chemotherapy.

Ann Allergy Asthma Immunol

November 2024

Section of Allergy and Immunology, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Electronic address:

View Article and Find Full Text PDF
Article Synopsis
  • Anaphylaxis is a life-threatening allergic reaction, and understanding its triggers is crucial for preventing severe cases known as refractory anaphylaxis (RA).
  • A study analyzed data from 1,378 patients diagnosed with anaphylaxis, finding that 3.3% had RA, with a history of anaphylaxis being the strongest risk factor.
  • Other factors such as the use of beta-blockers/ACE inhibitors, exposure to IV contrast agents, and symptoms of low blood pressure were also linked to increased severity, highlighting the need for prompt treatment to improve patient outcomes.
View Article and Find Full Text PDF

Background: Autoimmune diseases in children pose therapeutic challenges due to their refractory nature and the associated morbidity. Rituximab (RTX), a monoclonal antibody targeting CD20, has emerged as a promising steroid-sparing therapy for various autoimmune disorders by depleting B cells. However, its indications and safety in pediatric populations in our region remain insufficiently studied.

View Article and Find Full Text PDF

Systemic mastocytosis (SM) is a rare hematologic condition characterized by the proliferation and accumulation in tissue of clonal mast cells in multiple organ systems. The release of mast cell mediators in the indolent disease type and the predominant mast cell infiltration of tissues in advanced disease contribute to the heterogeneous clinical presentation. The disease driver in >90% of adult cases is an activating mutation, with D816V being the most frequent.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!